2,4-二(哌啶-1-基)苯胺 | 436096-88-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2,4-二(哌啶-1-基)苯胺
• 英文名称: Dipiperidino-(2,4)-anilin
• 英文别名: 2,4-dipiperidinylaminobenzene；2,4-Di(piperidin-1-yl)aniline
• CAS: 436096-88-7
• 化学式: C₁₆H₂₅N₃
• 分子量: 259.395
• InChiKey: CHRDROHURUMVLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-cyanofuran-2-carbonyl chloride 、 2,4-二(哌啶-1-基)苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 5-cyano-furan-2-carboxylic acid (2,4-di-piperidin-1-yl-phenyl)-amide
  参考文献：
  名称：

  Discovery of novel FMS kinase inhibitors as anti-inflammatory agents

  摘要：

  The optimization of the arylamide lead 2 resulted in identification of a highly potent series of 2,4-disubstituted arylamides. Compound 8 (FMS kinase IC50 = 0.0008 mu M) served as a proof-of-concept candidate in a collagen-induced model of arthritis in mice. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.059
• 作为产物：
  描述：

  4-(2-nitro-5-piperidinophenyl)piperidine 在 5%-palladium/activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以94%的产率得到2,4-二(哌啶-1-基)苯胺
  参考文献：
  名称：

  WO2006/47504

  摘要：

  公开号：

文献信息

• Inhibitors of c-fms kinase
  申请人：Illig R. Carl

  公开号：US20060100201A1

  公开（公告）日：2006-05-11

  The invention relates to compounds of Formula I: wherein A, X, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中A、X、R2和W在说明书中设置，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，它们抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了利用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移至骨骼。
• Isonipecotamides for the treatment of integrin-mediated disorders
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1533310A1

  公开（公告）日：2005-05-25

  The invention is directed to novel isonipecotamide derivatives of Formula (I), which are useful in treating integrin-mediated disorders.

  本发明涉及式（I）的新型异茴苯甲酰胺衍生物，可用于治疗整合素介导的疾病。
• Photoreactive ligands and uses thereof
  申请人：The Scripps Research Institute

  公开号：US11535597B2

  公开（公告）日：2022-12-27

  Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.

  本文公开了用于确定蛋白质作为与小分子配体相互作用的靶标的方法。本文还公开了用于分析可药用蛋白质的小分子配体和组合物。
• ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1133489B9

  公开（公告）日：2006-05-03
• AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1807407A1

  公开（公告）日：2007-07-18